A Multi-center, Randomized, Double-blind, Phase III Trial of SHR-1210 in Combination With Famitinib or Placebo Plus Chemotherapy in Subjects With Non-squamous Non-small-cell Lung Cancer.
Latest Information Update: 18 Oct 2023
At a glance
- Drugs Camrelizumab (Primary) ; Famitinib (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 19 Mar 2021 Added primary endpoints representing pharmacokinetic parameters.
- 11 Mar 2021 Status changed from not yet recruiting to recruiting.
- 10 Nov 2020 New trial record